New York University Langone Health
New York University Langone Health
New York, New York, United States18 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, hormone receptor-positive breast cancer, invasive breast carcinoma, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-10-06 | NCT04569747 | |
| An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic renal failure syndrome, kidney disorder, kidney failure, urinary system disorder | Recruiting | Not stated | 2026-09-25 | NCT05106387 | |
| A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Site, Skin and Connective Tissue Diseases, Thoracic Neoplasms, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, digestive system disorder, digestive system neoplasm, esophageal disorder, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 2 | 2026-09-23 | NCT04225117 | |
| Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic renal failure syndrome, kidney disorder, kidney failure, urinary system disorder | Recruiting | Phase 1 / Phase 2 | 2026-09-09 | NCT07224763 | |
| Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, Neoplasms, Nerve Tissue, adenocarcinoma, adenoma, carcinoma, cholangiocarcinoma, connective tissue neoplasm, epithelial neoplasm, fibrosarcoma, mesothelial neoplasm, mesothelioma, neoplasm, nerve sheath neoplasm, nervous system disorder, neurofibroma, neurofibrosarcoma, neuromuscular disease, peripheral nervous system disorder, peripheral nervous system neoplasm, sarcoma | Recruiting | Phase 1 / Phase 2 | 2026-09-08 | NCT05732831 | |
| A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) | Cholangitis, Sclerosing, Digestive System Diseases, Pathological Conditions, Signs and Symptoms, Pruritus, Signs and Symptoms, Skin Manifestations, Skin and Connective Tissue Diseases, bile duct disorder, biliary tract disorder, cholangitis, cholestasis, primary sclerosing cholangitis, skin disorder | Active, not recruiting | Phase 2 | 2026-08-26 | NCT04663308 | |
| ATEMPT 2.0: Adjuvant T-DM1 vs TH | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 2 | 2026-08-19 | NCT04893109 | |
| A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Neoplasms by Histologic Type, Neoplasms, Nerve Tissue, hereditary disease, hereditary neoplastic syndrome, inherited neurodegenerative disorder, neoplasm, nerve sheath neoplasm, nervous system disorder, neurocutaneous syndrome, neurodegenerative disease, neurofibroma, neurofibromatosis, neurofibromatosis type 1, neuromuscular disease, peripheral nervous system disorder, peripheral nervous system neoplasm, plexiform neurofibroma | Recruiting | Phase 2 | 2026-07-29 | NCT06541847 | |
| A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Not yet recruiting | Phase 1 | 2026-07-23 | NCT07722767 | |
| Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors | Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, adenocarcinoma, bronchial neoplasm, bronchogenic carcinoma, carcinoma, epithelial neoplasm, lung adenocarcinoma, lung cancer, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-07-06 | NCT05887492 | |
| Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-06-30 | NCT06162221 | |
| A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, adenoid cystic carcinoma, breast cancer, breast disorder, breast neoplasm, carcinoma, endocrine system disorder, endometrium neoplasm, epithelial neoplasm, fallopian tube cancer, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, skin disorder, triple-negative breast carcinoma, uterine disorder | Recruiting | Phase 1 / Phase 2 | 2026-06-29 | NCT05377996 | |
| A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-06-17 | NCT04036682 | |
| A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA) | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic renal failure syndrome, kidney disorder, kidney failure, urinary system disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-06-02 | NCT05092347 | |
| DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) | Noonan syndrome 5, low grade glioma | Active, not recruiting | Phase 3 | 2026-05-14 | NCT05566795 | |
| Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic renal failure syndrome, kidney disorder, kidney failure, urinary system disorder | Recruiting | Phase 1 / Phase 2 | 2026-03-27 | NCT06878560 | |
| Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, vascular disorder | Active, not recruiting | Phase 3 | 2026-02-27 | NCT05581303 | |
| Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants | Amyloid Neuropathies, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Nutritional and Metabolic Diseases, amyloidosis, familial amyloid neuropathy, hereditary amyloidosis, hereditary disease, inborn errors of metabolism, inherited neurodegenerative disorder, metabolic disease, nervous system disorder, neurodegenerative disease, neuromuscular disease, peripheral nervous system disorder, proteostasis deficiencies | Active, not recruiting | Phase 3 | 2025-10-14 | NCT04988386 |